U of A spinoff, U.S. firm merge to commercialize transplant technology

Cardiac surgery professors Jayan Nagendran (left) and Darren Freed with the EVOSS system they developed to extend the time donated lungs can be kept healthy while they are transported for transplant. The innovative technology took a major step toward approval, manufacture and global distribution with the merger of the U of A spinoff company Tevosol and the U.S.-based medical tech company Bridge to Life. (Photo: University Hospital Foundation)

Reading Time: 5 minutes Bridge to Life commits US$10 million to clinical trial and commercial development of Tevosol Ex-Vivo Organ Support System

Stem cell therapy research for Type 1 diabetes receives funding

Greg Korbutt (left) and Andrew Pepper are members of a research team aiming to develop insulin-producing stem cells that won’t trigger an immune response, so transplant patients wouldn't need to take anti-rejection drugs. (Photo: Faculty of Medicine & Dentistry, May 2019)

Reading Time: 5 minutes Three U of A researchers will help lead projects to advance treatments for patients

Pin It on Pinterest